Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROGAINE (FOR WOMEN) vs MEN'S ROGAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.
Minoxidil is a potassium channel opener that increases cutaneous blood flow and stimulates hair follicles through vasodilation and direct mitogenic effects on dermal papilla cells, prolonging the anagen phase and increasing hair follicle size.
FDA-approved: Treatment of female androgenetic alopecia (female pattern hair loss) in women aged 19-49 years with mild to moderate hair loss,Off-label: Treatment of male pattern baldness (off-label for women if used for this purpose), alopecia areata, and other forms of hair thinning
FDA-approved for the treatment of androgenetic alopecia (male pattern baldness) in men aged 18-49 with mild to moderate hair loss at the vertex (top of scalp).
Apply 1 m L of 2% minoxidil solution topically to the scalp twice daily (total 2 m L per day).
Topical 5% solution: apply 1 m L to scalp twice daily. Max: 2 m L/day.
The terminal elimination half-life of minoxidil is approximately 4.2 hours (range 2–7 hours) following topical application, but the pharmacodynamic half-life (duration of drug presence in the skin and hair follicle) is longer, estimated at 24 hours. For oral minoxidil, the terminal half-life averages 4.5 hours (range 3–7 hours).
The terminal elimination half-life of minoxidil after topical administration is approximately 4.2 hours (range 2.5–4.7 hours) in patients with normal renal function. This short half-life necessitates twice-daily application to maintain steady-state concentrations for continuous hair growth stimulation.
Minoxidil is primarily metabolized in the liver via glucuronidation to minoxidil glucuronide, which is inactive. Minor metabolism via sulfation may occur. The metabolism is mediated by UDP-glucuronosyltransferases (UGTs).
Minoxidil is primarily metabolized by conjugation with glucuronic acid (via UGT1A1) to form minoxidil N-glucuronide; also undergoes sulfation and minor oxidative metabolism.
Renal excretion of unchanged minoxidil and its glucuronide conjugates accounts for approximately 95% of the absorbed dose; about 5% is eliminated unchanged in feces via biliary excretion.
Approximately 60% of topical minoxidil is absorbed systemically. The absorbed dose is primarily excreted via the kidneys as unchanged minoxidil and its glucuronide and sulfate conjugates. Renal excretion accounts for about 95% of elimination, with fecal excretion (~5%) being minor. Unabsorbed drug is eliminated in feces via desquamation and washing.
Minoxidil is approximately 20% bound to serum proteins, primarily albumin, with negligible binding to alpha-1-acid glycoprotein.
Minoxidil is approximately 20% bound to plasma proteins (primarily albumin). Binding is low and not concentration-dependent over the therapeutic range.
The apparent volume of distribution for minoxidil is 3.5 L/kg (range 2.5–4.5 L/kg), indicating extensive extravascular distribution and tissue binding, particularly to vascular smooth muscle.
The apparent volume of distribution (Vd) of minoxidil after intravenous administration is approximately 3.3 L/kg (range 2.5–4.2 L/kg), indicating extensive distribution into tissues. This large Vd is consistent with its lipophilicity and penetration into hair follicles and skin.
Absolute bioavailability of topical minoxidil is approximately 1.5% (range 0.3–3.2%) of the applied dose, due to low percutaneous absorption and extensive first-pass metabolism in the skin. Oral minoxidil has an absolute bioavailability of 90%.
Bioavailability of minoxidil from topical 5% solution is approximately 1.5% (range 0.3–4.5%) of the applied dose, based on urinary recovery. The 2% solution yields similar relative bioavailability (about 1.4%). Systemic absorption is minimal, with most drug remaining in the skin and hair follicles.
No dosage adjustment required for renal impairment.
No dose adjustment required for topical use; systemic absorption minimal.
No dosage adjustment required for hepatic impairment.
No dose adjustment required for topical use; systemic absorption minimal.
Safety and efficacy not established; use is not recommended.
Safety and efficacy not established in patients under 18 years; not recommended.
No specific dose adjustment; use with caution due to potential increased sensitivity.
No specific dose adjustment; use same as adults but monitor for systemic effects due to possible skin atrophy and reduced renal function.
None for topical minoxidil (Rogaine for Women). Oral minoxidil (not this formulation) carries a boxed warning for adverse cardiovascular effects.
None
Systemic absorption can cause cardiovascular effects such as tachycardia, fluid retention, and hypotension (rare with topical use),May cause local skin reactions: irritation, redness, itching, or dryness,Potential for increased hair loss initially (shedding of telogen hairs) during first 2-6 weeks,Avoid contact with eyes, mucous membranes, and broken skin,Use caution in patients with underlying cardiovascular disease (angina, arrhythmias, heart failure),Discontinue if systemic side effects occur or if no improvement after 6 months
May cause hypotension if absorbed systemically; avoid use on broken or irritated scalp; discontinue if scalp irritation, redness, or burning occurs; not effective for receding hairlines; palpitations, edema, or dizziness may indicate systemic absorption; use caution in patients with cardiovascular disease or hypertension.
Hypersensitivity to minoxidil or any component of the formulation,Use on broken, irritated, or sunburned scalp,Concomitant use with other topical agents that may increase absorption (e.g., corticosteroids, tretinoin),Relative: Pregnancy and breastfeeding (minoxidil is pregnancy category C; use only if benefit outweighs risk)
Hypersensitivity to minoxidil or any component of the formulation; use in women (not indicated); use in patients with pheochromocytoma; application to a shaved or damaged scalp.
No clinically significant food interactions. Avoid excessive caffeine or stimulants as they may exacerbate anxiety or palpitations (rare systemic absorption).
No known food interactions. Avoid grapefruit juice? Not reported with topical minoxidil. No dietary restrictions.
Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Systemic absorption is minimal (<1.5%) with recommended topical use, but it is classified as pregnancy category C. First trimester: theoretical risk, avoid use. Second and third trimesters: minimal known risk but use only if clearly needed.
Topical minoxidil (MEN'S ROGAINE) has limited systemic absorption; however, based on animal studies and case reports, it is classified as Pregnancy Category C. First trimester: No adequate human studies; animal studies show some fetal abnormalities at high doses. Second and third trimesters: Theoretical risk of fetal hypotension and altered hair growth; avoid use unless potential benefit outweighs risk.
Minoxidil is excreted in human milk following oral administration; however, data after topical use are lacking. The milk-to-plasma ratio (M/P) is unknown for topical application. Due to potential for adverse effects in the nursing infant (e.g., hypotension), breastfeeding is not recommended during treatment.
Minoxidil is excreted into breast milk in low amounts; the milk-to-plasma (M/P) ratio is unknown. Systemic absorption from topical application is minimal (approximately 1.4-2%), but due to potential adverse effects (e.g., hypotension) in the nursing infant, it is generally not recommended during breastfeeding.
No dose adjustments are recommended based on pharmacokinetic changes in pregnancy, as systemic absorption is minimal. However, use during pregnancy is generally discouraged. If used, the standard dose (2% or 5% solution, 1 m L twice daily) should not be exceeded.
No dosing adjustment is recommended for topical minoxidil during pregnancy due to minimal systemic exposure; however, use is generally avoided per precaution. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are unlikely to be clinically significant given the route and low absorption.
Minoxidil 5% foam is first-line for female pattern hair loss (FPHL). Response requires 4-6 months of consistent use; counsel patients not to expect immediate results. Initial shedding may occur in first 2-6 weeks due to telogen effluvium; this is a positive sign of drug activity. Discontinue if scalp irritation or hypertrichosis develops. Avoid use on broken or sunburned skin. Apply to dry scalp, not to hair shaft.
Men's Rogaine contains minoxidil 5%, which is FDA-approved for androgenetic alopecia in men. Application requires direct scalp contact; avoid hair interference. Initial shedding may occur due to telogen phase synchronization. Response requires 4-6 months of twice-daily application; discontinuation leads to regrowth loss within 3-4 months. Adverse effects include contact dermatitis, hypertrichosis, and rare cardiovascular effects (tachycardia, edema) due to systemic absorption.
Apply 1/2 capful of foam to dry scalp once daily, no need to rinse.,Results take at least 4 months; continue use to maintain regrowth.,Initial hair shedding is temporary and normal.,Do not use if pregnant or breastfeeding.,Avoid contact with eyes; if contact occurs, rinse with cool water.,Wash hands after application.,Do not use on other body parts.
Apply twice daily to dry scalp, not to wet hair.,Use the dropper or spray directly onto the balding area; do not use more than 1 m L per dose.,Wash hands thoroughly after application.,Do not apply to other areas of the body to avoid unwanted hair growth.,Avoid contact with eyes, nose, or mucous membranes; rinse immediately with water if contact occurs.,Monitor for scalp irritation; discontinue if severe redness or itching occurs.,Consistency is key; missed doses reduce efficacy.,Hair loss may temporarily increase in first 2-6 weeks; this is normal.,Results are best visible after 4-6 months of regular use.,If no results after 1 year, discontinue use.,Do not use with other topical products on the scalp within 2 hours of application.,Avoid inhalation of spray; use in a well-ventilated area.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROGAINE (FOR WOMEN) vs MEN'S ROGAINE, answered by our medical review team.
ROGAINE (FOR WOMEN) is a Hair Growth Agent that works by Minoxidil is a potassium channel opener. It causes vasodilation by opening ATP-sensitive potassium channels in vascular smooth muscle cells, leading to hyperpolarization and relaxation of arteriolar smooth muscle. This improves blood flow to hair follicles and prolongs the anagen phase of hair growth, possibly by increasing vascular endothelial growth factor (VEGF) and other growth factors.. MEN'S ROGAINE is a Topical Hair Growth Agent that works by Minoxidil is a potassium channel opener that increases cutaneous blood flow and stimulates hair follicles through vasodilation and direct mitogenic effects on dermal papilla cells, prolonging the anagen phase and increasing hair follicle size.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROGAINE (FOR WOMEN) and MEN'S ROGAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROGAINE (FOR WOMEN) is: Apply 1 m L of 2% minoxidil solution topically to the scalp twice daily (total 2 m L per day).. The standard adult dose of MEN'S ROGAINE is: Topical 5% solution: apply 1 m L to scalp twice daily. Max: 2 m L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROGAINE (FOR WOMEN) and MEN'S ROGAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROGAINE (FOR WOMEN) is classified as Category C. Topical minoxidil (Rogaine for Women) has limited human pregnancy data. Animal studies show no teratogenic effects at systemic exposures up to 5 times the human topical dose. Syste. MEN'S ROGAINE is classified as Category C. Topical minoxidil (MEN'S ROGAINE) has limited systemic absorption; however, based on animal studies and case reports, it is classified as Pregnancy Category C. First trimester: No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.